Epigenomics & Biochain colorectal cancer early detection kit approved by CFDA

Source: Biovalley, December 12, 2014, epigenomics and Biochain recently announced that China food and Drug Administration (CFDA) approved the sale of epiprocolon in China EPI procolon is a non-invasive blood diagnostic test kit for colorectal cancer This approval is based on the key clinical validation completed by Biochain in May 2014, which proves the outstanding performance of EPI procolon in clinical testing This peripheral blood cancer screening product can detect 75% of cancers with a specificity of 97.5% It has great potential to become an important tool for establishing and expanding colorectal cancer screening in China Because the screening is based on blood samples, it is simple and easy to operate, which can make more subjects participate in colorectal cancer screening work, and provide support for reducing advanced cancer cases and treatment costs Biochain, the partner of epigenomics in China, hopes to push the kit to the Chinese market through the established sales pipeline next week At present, Biochain is actively preparing for sales James Wang, chairman of Biochain, said the approval of EPI procolon by CFDA was good news and a milestone for the company The kit has high sensitivity and specificity, and can meet the needs of Chinese people and Society for colorectal cancer detection Epi proColon not only provides early diagnosis for reducing the incidence rate and mortality of colorectal cancer, but also enhances the awareness of early screening, diagnosis and intervention in the public, and promotes the health of the people At present, the company is actively promoting the application of EPI procolon in colorectal cancer screening in China About epigenomics Epigenomics is a molecular diagnostics company specializing in the development and sale of cancer-related patented products The company's products are mainly used for early and accurate detection of cancer EPI procolon, the main product of epigenomics, is a blood test kit for the early screening of colorectal cancer At present, its main market is Europe The product has just been approved by CFDA and is in the process of FDA approval In addition, epigenomics also sells the lung cancer tissue detection kit EPI prolung in the European market, and its products are certified by many diagnostic giants, partners and laboratories Epigenomics is a multinational company operating mainly in Europe and the United States About Biochain Biochain is a manufacturer of biotechnology tools and advanced molecular diagnostic reagents based in the United States and China Biochain owns and operates its own independent laboratory, Beijing Biochain medical laboratory The laboratory is mainly engaged in the research of molecular diagnosis related technologies and products, mainly engaged in the field of reproductive health and cancer research, and also provides cell and molecular level technical services for the detection of various stages and types of diseases.